KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 72 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2014. The put-call ratio across all filers is 1.04 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $194,285 | -67.3% | 108,539 | -28.9% | 0.00% | -100.0% |
| Q1 2023 | $593,587 | +23.0% | 152,593 | +7.5% | 0.00% | 0.0% |
| Q4 2022 | $482,541 | -36.5% | 141,924 | +2.0% | 0.00% | 0.0% |
| Q3 2022 | $760,000 | +21.4% | 139,141 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $626,000 | -38.6% | 138,696 | +0.4% | 0.00% | 0.0% |
| Q1 2022 | $1,020,000 | +156.3% | 138,158 | +122.3% | 0.00% | – |
| Q4 2021 | $398,000 | -20.1% | 62,143 | -27.4% | 0.00% | – |
| Q3 2021 | $498,000 | -42.5% | 85,614 | +2.0% | 0.00% | – |
| Q2 2021 | $866,000 | -8.4% | 83,964 | -6.6% | 0.00% | – |
| Q1 2021 | $945,000 | -71.5% | 89,865 | -58.0% | 0.00% | -100.0% |
| Q4 2020 | $3,312,000 | +0.2% | 213,933 | -5.5% | 0.00% | 0.0% |
| Q3 2020 | $3,306,000 | -25.5% | 226,435 | -3.3% | 0.00% | -33.3% |
| Q2 2020 | $4,436,000 | +156.0% | 234,235 | +159.7% | 0.00% | +200.0% |
| Q1 2020 | $1,733,000 | -20.6% | 90,198 | -20.8% | 0.00% | -50.0% |
| Q4 2019 | $2,183,000 | +441.7% | 113,861 | +171.3% | 0.00% | – |
| Q3 2019 | $403,000 | -29.5% | 41,961 | -56.1% | 0.00% | -100.0% |
| Q2 2019 | $572,000 | -5.1% | 95,650 | -7.4% | 0.00% | 0.0% |
| Q1 2019 | $603,000 | -2.4% | 103,323 | +56.5% | 0.00% | 0.0% |
| Q4 2018 | $618,000 | -21.2% | 66,006 | +43.3% | 0.00% | 0.0% |
| Q3 2018 | $784,000 | -1.5% | 46,064 | -1.7% | 0.00% | 0.0% |
| Q2 2018 | $796,000 | +28.6% | 46,837 | +1.6% | 0.00% | 0.0% |
| Q1 2018 | $619,000 | +61.2% | 46,089 | +15.1% | 0.00% | – |
| Q4 2017 | $384,000 | +9.1% | 40,053 | +25.0% | 0.00% | – |
| Q3 2017 | $352,000 | +262.9% | 32,039 | +198.3% | 0.00% | – |
| Q2 2017 | $97,000 | -50.8% | 10,739 | -30.0% | 0.00% | – |
| Q1 2017 | $197,000 | +17.3% | 15,331 | -14.2% | 0.00% | – |
| Q4 2016 | $168,000 | -30.6% | 17,859 | -28.0% | 0.00% | – |
| Q3 2016 | $242,000 | +80.6% | 24,818 | +24.3% | 0.00% | – |
| Q2 2016 | $134,000 | -78.7% | 19,963 | -58.0% | 0.00% | -100.0% |
| Q4 2015 | $630,000 | -63.0% | 47,579 | -23.9% | 0.00% | -50.0% |
| Q2 2015 | $1,701,000 | +88.4% | 62,535 | +112.0% | 0.00% | +100.0% |
| Q1 2015 | $903,000 | +31.8% | 29,500 | +61.1% | 0.00% | 0.0% |
| Q4 2014 | $685,000 | +150.9% | 18,309 | +134.3% | 0.00% | – |
| Q3 2014 | $273,000 | -3.2% | 7,814 | +28.8% | 0.00% | – |
| Q2 2014 | $282,000 | -25.8% | 6,069 | -50.6% | 0.00% | – |
| Q1 2014 | $380,000 | – | 12,291 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,200,396 | $30,084,000 | 1.72% |
| TFS CAPITAL LLC | 105,040 | $987,000 | 0.26% |
| Tekla Capital Management LLC | 500,324 | $4,703,000 | 0.20% |
| Piermont Capital Management Inc. | 51,080 | $480,000 | 0.11% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 55,793 | $524,000 | 0.09% |
| Candriam S.C.A. | 390,000 | $3,666,000 | 0.08% |
| Virtus ETF Advisers LLC | 27,446 | $258,000 | 0.08% |
| SECOR Capital Advisors, LP | 66,484 | $625,000 | 0.08% |
| Trexquant Investment LP | 29,007 | $273,000 | 0.04% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 32,196 | $303,000 | 0.04% |